BNP Rapid Test

Product information

The BNP (Brain Natriuretic Peptide) is a rapid screening test for the detection of human BNP in whole blood, serum or plasma samples to be used as an aid by medical healthcare professionals in assessing cardiac disorders such as congestive heart failure.

Advantages of BNP test

• Easy to perform
• No complex sample collection needed
• Accurate test result

General information

Brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) are a family of structurally related peptides that participate in the integrated control of renal and cardiovascular function. BNP as well as NT-proBNP, which are not present in normal myocardium, are the products of proteolytic processing of proBNP molecule for which concentration increases with cardiovascular events such as heart failure, acute coronary syndromes or cardiomyopathy.

BNP and NT-proBNP have therefore gained widespread acceptance as important tools for diagnosis and risk stratification in the acute care setting. In healthy adults, plasma levels of BNP is below 100 pg/mL and raises rapidly over 400 pg/mL in case of cardiac dyspnea. It has been demonstrated than BNP has a better diagnostic value when compared to NT-proBNP in case of elderly patients, renal insufficiency or after AMI treatment.

BNP is a rapid qualitative assay for the detection of BNP in serum, plasma or whole blood samples. The method is based on a unique combination of monoclonal dye conjugate and monoclonal antibody immobilized on the solid phase to identify BNP in the test samples with a high degree of specificity. As the test sample flows through the absorbent device, the labelled antibody-dye conjugate binds to the BNP forming an antibody-antigen complex. This complex binds to the anti-BNP antibody in the reaction zone and produces a pink-rose colored band, when the BNP concentration is higher than 100 pg/mL.

The sole measurement of BNP concentration is not sufficient to diagnose heart failure or other cardiac dysfunctions. Additional clinical examinations such as echography or echocardiogram are generally necessary to confirm the diagnosis. In the absence of BNP, there is no line in the reaction zone.

The mixture continues flowing through the absorbent device past the reactive zone and control zone. Unbound conjugate binds to the reagents in the control zone, producing a pink-rose colored band, demonstrating that the reagents are functioning correctly.

Test procedure

1. Allow specimen and BNP Rapid Test to come to room temperature prior to testing.
2. Remove the reaction device from its protective wrapper by tearing along the split.
3. Label device with the patient ‘s name or control number.
4. Fill the serum dropper with specimens (serum, plasma or whole blood) and by holding it vertically, dispense one drop (25 μL) into sample well. If whole blood is used, dispense 2 drops (50 μL) into the sample well and wait for the whole blood sample to be completely absorbed before adding diluent.
5. Hold the diluent vial vertically and add exactly 6 drops (200 μL) of diluent into the sample well (▷) with an interval of 2-3 seconds between each drop.
6. Read the results after 15 minutes. Do not interpret after 20 minutes.

Interpretation of the results

Negative result: One colored band appears in the control zone. No apparent band in the test zone.

Positive result: In addition to the control band a clearly distinguishable band also appears on the test zone.

Invalid result: If there is no distinct colored band visible the control zone, the test is inconclusive for the corresponding parameter. In this case, it is recommended that the test be repeated.